Licensing And Co-development Deals 'Bridge Gap' to Drug Commercialisation

A report by consulting firm Cutting Edge Information has underlined the benefits of licensing and co-development deals.

Licensing and co-development deals can help to bridge the gap between drug discovery and development to commercialisation, a consulting firm has claimed.

According to Cutting Edge Information, the skills required to complete regulatory submission and plan and execute a global drug launch are entirely different to those needed to conduct earlier clinical trials.

It can be disastrous to attempt to combine the two stages if a pharmaceutical or biotech company does not have the necessary expertise.

Adam Bianchi, Cutting Edge Information's chief operating officer, explained that "even a perfect focus on clinical will not translate to the commercial side without adding substantial expertise and budge